title: The clinical implications of the prostate cancer prevention trial.
authors: Department of Urology, University of Vienna Medical School, Vienna, Austria.
authors: M
authors: M
authors: Marberger
authors: J
authors: J
authors: Adolfsson
authors: A
authors: A
authors: Borkowski
authors: J
authors: J
authors: Fitzpatrick
authors: D
authors: D
authors: Kirk
authors: D
authors: D
authors: Prezioso
authors: C
authors: C
authors: Rabaça
authors: E
authors: E
authors: Solsona
authors: P
authors: P
authors: Teillac
mesh_terms: D000368:Aged; D003951:Diagnostic Errors; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen